SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (487)5/16/2012 10:00:58 AM
From: Biomaven  Read Replies (1) of 508
 
Jim,

do you think that there will be side effects of the CTGF mAb on chondrogenesis or osteogenesis, such as an increase in bone fractures upon longer term treatment? Knockout mice have shown such signals based on my earlier review of the literature.
I think that only time will tell on a question like this. The effect seems much less in adult mice and the mAb isn't going to abrogate all CTGF action. The issue is obviously less important in fatal diseases such as IPF or pancreatic cancer, but may be more of an issue in liver fibrosis. Worst case is probably patients need to take some drug holidays.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News